 RedHill Biopharma NASDAQ:RDHL announced that South Africa has joined the US in approving the Phase 23 study of its once-daily, orally administered pill RHB-107 upamostat for non-hospitalized patients with symptomatic coronavirus COVID-19. The specialty biopharmaceutical company said the study is already ongoing in the US, with expansion of study sites underway to further accelerate recruitment. 